License for Use of "Physicians' Current Procedural Terminology", (CPT) Fourth Edition

End User/Point and Click Agreement: CPT codes, descriptions and other data only are copyright 2009 American Medical Association (AMA). All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the AMA.

You, your employees and agents are authorized to use CPT only as contained in the following authorized materials including but not limited to CGS fee schedules, general communications, Medicare Bulletin, and related materials internally within your organization within the United States for the sole use by yourself, employees, and agents. Use is limited to use in Medicare, Medicaid, or other programs administered by the Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized here in must be obtained through the AMA, CPT Intellectual Property Services, 515 N. State Street, Chicago, IL 60610. Applications are available at the AMA website.

This product includes CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, 515 North State Street, Chicago, Illinois, 60610. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2)(June 1995) and/or subject to the restrictions of DFARS 227.7202-1(a)(June 1995) and DFARS 227.7202-3(a)June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (June 1987) and/or subject to the restricted rights provisions of FAR 52.227-14 (June 1987) and FAR 52.227-19 (June 1987), as applicable, and any applicable agency FAR Supplements, for non-Department Federal procurements.

AMA Disclaimer of Warranties and Liabilities.

CPT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. AMA warrants that due to the nature of CPT, it does not manipulate or process dates, therefore there is no Year 2000 issue with CPT. AMA disclaims responsibility for any errors in CPT that may arise as a result of CPT being used in conjunction with any software and/or hardware system that is not Year 2000 compliant. No fee schedules, basic unit, relative values or related listings are included in CPT. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this file/product is with CGS or the CMS and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

CMS Disclaimer

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT must be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CPT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL CONTAINED ON THIS PAGE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

This license will terminate upon notice to you if you violate the terms of this license. The AMA is a third party beneficiary to this license.

POINT AND CLICK LICENSE FOR USE OF "CURRENT DENTAL TERMINOLOGY", ("CDT")

End User License Agreement

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN.

IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use CDT-4 only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT-4 is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT-4. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT-4 for resale and/or license, transferring copies of CDT-4 to any party not bound by this agreement, creating any modified or derivative work of CDT-4, or making any commercial use of CDT-4. License to use CDT-4 for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association website.
Applicable Federal Acquisition Regulation Clauses (FARS)\Department of Defense Federal Acquisition Regulation Supplement (DFARS) Restrictions Apply to Government use. Please click here to see all U.S. Government Rights Provisions.
ADA DISCLAIMER OF WARRANTIES AND LIABILITIES. CDT-4 is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CDT-4. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for the software, including any CDT-4 and other content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The ADA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT-4 should be addressed to the ADA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CDT-4. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I ACCEPT". If you do not agree to the terms and conditions, you may not access or use the software. Instead, you must click below on the button labeled "I DO NOT ACCEPT" and exit from this computer screen.

Print | Bookmark | Font Size: + | –

2013 3rd Quarter Payment Allowance Limits for Not Otherwise Classified (NOC) Drugs

Effective July 1, 2013 through September 30, 2013

Revised: 06.24.14

Name of Drug and EXACT Dosage Given MUST be in Block 19 (paper), as an Attachement, or Narrative Field (EMC)

Payment allowance limits subject to the ASP methodology are based on 2Q12 ASP data.

Providers should contact their local Medicare contractor processing the claim for the most appropriate unlisted/unclassified HCPCS code to use in reporting these drugs to Medicare.

** - Carrier Priced

The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific olumn does not indicate Medicare coverate of the drug in that specific category. These determinations shall be made by the local Medicare Contractor processing the claim.

Drug Name	NDC Number	Dosage	Current PAR	Current NON-PAR	Notes
Abatacept (Orencia) The subcutaneous form of abatacept is considered self-administered
Ado-Trastuzumab Emtansine (Kadcyla) covered indications HER2-positive, metastatic breast cancer (174.0-175.9)		10 mgs.	$293.998	$279.298	Added March 2013
Alfentanil Hydrochloride (Alfenta)		500 mcg/5 ml	$1.977	$1.878
Alglucosidase Alfa (Myozyme)		10 mg
Allopurinol Sodium (Aloprim) ICD-9's 274.9 or 790.6 plus the ICD-9 for the neoplasm. Need name of chemotherapy agent causing the elevation of uric acid and a statement as to why patient can not tolerate oral form of the drug.		500 mg/SDV	$320.671	$304.637
Afinitor (see Everolimus)
Aflibercept (see EYLEA)					code for 2013-J0178
Amidate (see Etomidate)
Amino Acid		500 ml	$21.110	$20.055
Amino Acid		1000 ml	$35.190	$33.431
Aminocaproic Acid		250 mg	$0.073	$0.069
Arginine Hydrochloride (R-Gene 10)		300 ml	$11.225	$10.664
Arzerra (see Ofatumumab)
** Ascorbic Acid (Vitamin C) (Cenolate) Non-covered by Carrier
** Atenolol (Tenormin) ICD-9's = 401.0 - 429.9		0.5 mg / ml	$0.800	$0.760
Atropine Sulfate / Edrophonium Chloride		10 mg	$1.651	$1.568
Avastin (See Bevacizumab)
Aztreonam (Azactam)		500 mg	$12.863	$12.220
** Bacitracin (Bacim)		50,000 U	$10.170	$9.662
Belimumab (Benlysta) Covered ICD-9: 710.0		10 mg
Beltatacept (Nulojix) Covered indications: V420 and 075 or 996.52		250 mg.	$978.380	$929.461
Benlysta (see Belimumab)
Berinert (see C1 Esterase Inhibitor)
Bevacizumab (Avastin) CPT 67028 must be on claim or in history; allow if billed with J3490 or J3590 and the ICD-9 requirements from one of the following codes: 115.02, 115.12, 115.92, 362.01 - 362.07 (any), 362.16, 362.35 - 362.37 (any), 362.42, 362.52 or 362.83.		N/A	$60.000	$57.000
Bivigam	59730-6503-01	500 mg	$63.579	$60.400	added June 2013
Bivigam	59730-6502-01	500 mg	$63.579	$60.400	added June 2013
Bretylium Tosylate (Bretylol)		5 mg	$0.175	$0.166
Brevibloc (see Esmolol Hydrochloride)
Brovana (see Arformoterol Tartrate)
Bumetanide (Bumex)		0.25 mg	$0.208	$0.198
Bupivacaine Hcl, 0.25%, 2 ml (Considered Part of Procedure)
Bupivacaine Hcl, 0.50%, 2 ml (Considered Part of Procedure)
Bupivacaine, Sterile, 0.25%/10ml (Sensorcaine, Sterile) Allowed when billed with 51700, 51720, 62310, 62311, 62318, 62319, 62368, 64400 - 64484, 64505 - 64530, 77003, 95990, or 96530. When billed with other procedures, considered part of procedure performed.		0.25% - 1 ml	$0.096	$0.091
Bupivacaine, Sterile, 0.50%/10ml (Sensorcaine, Sterile) Allowed when billed with 51700, 51720, 62310, 62311, 62318, 62319, 62368, 64400 - 64484, 64505 - 64530, 77003, 95990, or 96530. When billed with other procedures, considered part of procedure performed.		0.50% - 1 ml	$0.096	$0.091
Bupivacaine, Sterile, 0.75%/10ml (Sensorcaine, Sterile) Allowed when billed with 51700, 51720, 62310, 62311, 62318, 62319, 62368, 64400 - 64484, 64505 - 64530, 77003, 95990, or 96530. When billed with other procedures, considered part of procedure performed.		0.75% - 1 ml	$0.096	$0.091
Cabazitaxel (Jevtana®)		1 mg
Calciferol (see Ergocalciferol D2)
Calcium Chloride		100 mg / ml	$0.159	$0.151
Candida Antigen Non covered by carrier
Cardizem IV (see Diltiazem Hydrochloride)
Carfilzomib (Kyprolis) covered ICD-9 203.00 or 203.02		1 mg	$29.291	$27.826	Updated April 2013
** Cefamanadole Nafate (Mandol)		1 gm	$8.610	$8.180
** Cefoperazone Sodium (Cefobid)		1 gm	$16.380	$15.561
Cefotetan Disodium (Cefotan)		1 gm	$11.376	$10.807
**Cenolate (Vitamin C) (Ascorbic Acid) Non covered by carrier
Chirocaine (see Levobupivacaine Hydrochloride)
Cimetidine Hcl. (Tagamet)		150 mg	$1.064	$1.011
Cimzia (see Certolizumab Pegol)
Clavulanate Potassium / Ticarcillin Disodium		0.1 - 3 gm	$11.800	$11.210
Clevidipine Butyrate		1 mg	$2.834	$2.692
Clindamycin Phosphate (Cleocin)		150 mg	$1.871	$1.777
Clorpactin WCS-90 (see Oxychlorosene Sodium)
Copper Sulfate		0.4 mg	$0.125	$0.119
Cystografin (see Diatrizoate Meglumine)
Dantrolene Sodium		20 mg	$78.800	$74.860
Denileukin Difitox (Ontak) (For 300 mcg, use code J9160)		150 mcg	$595.430	$565.659
Denosumab (Prolia ™ or Xgeva) If Prolia ™, covered ICD-9 = 733.01; if Xgeva, covered ICD-9 = 198.5.		1 mg
Depacon (see Valproate Sodium)
Depakene - Non covered by carrier
Depakote Non covered by carrier
Depakote ER - Non covered by carrier
Depakote Sprinkles-Non covered by carrier
Dextrose 2.5%		2.50%	$7.680	$7.296
Dextrose 5%		5%	$7.860	$7.467
Dextrose 10%		500 ml	$10.000	$9.500
Dextrose 50%		50 ml	$0.101	$0.096
** Dextrose / Nitroglycerin 5%-20 mg/ 100 ml/250 ml		20 mg/100 ml/250 ml	$6.320	$6.004
** Dextrose 5% / Sodium Chloride		1000 ml	$11.220	$10.659
Diatrizoate Meglumine (Cystografin)		10 ml	$2.10	$2.00
Diltiazem Hydrochloride (Cardizem IV)		5 mg	$0.203	$0.193
Diprivan (see Propofol)
Divalproex Sodium- Non covered by carrier
Divalproex Sodium ER- Non covered by carrier
Doxapram Hydrochloride (Dopram)		20 mg	$2.195	$2.085
Doxycycline Hyclate		100 mg	$15.027	$14.276
Edecrin Sodium (see Ethacrynate Sodium)
Edrophonium Chloride (Tensilon) (Allow for ICD9 - 358.0)		10 mg	$2.420	$2.299
Elaprase (see Idursulfase)
Emend for Injection (see Fosaprepitant Dimeglumine)
Enalaprilat (Vasotec IV)		1.25 mg	$1.142	$1.085
Eovist (see Gadoxetate Disodium)
Ergocalciferol D2 (Calciferol) ICD-9's = 579.8 or 579.9 Allowed when administered in physician's office		500,000 IU/ 1ml	$29.840	$28.348
Eribulin Mesylate (Halaven) - Covered ICD-9's = 174.0 - 174.9		0.1 mg
Esmolol Hydrochloride (Brevibloc) Covered ICD-9 = 427.89 (Dosage change from 100 mg to 10 mg.)		10 mg	$0.788	$0.749
Esomeprazole Sodium (Nexium IV) Covered ICD-9's = 530.10 - 530.19 or 530.81 when administered in the physician's office.		20 MG	$18.372	$17.453
Estradiol		1 gram	$13.300	$12.635
** Estradiol Pellets		Per Pellet	Invoice	Invoice
Ethacrynate Sodium (Edecrin Sodium)		50 mg	$19.040	$18.088
** Ethiodized Oil (Ethiodol)		1 ml	$8.060	$7.657
Etomidate (Amidate)		2 mg	$0.723	$0.687
Everolimus (Afinitor / Zortress) - Non-Covered; Oral drug considered as self-administered.
EYLEA (see Aflibercept)
Famotidine (Pepcid)		10 mg	$0.370	$0.352
Ferric Carboxymaltose (Injectafer) Covered for iron-deficiency anemia: Treatment of iron-deficiency anemia in adults (280.0, 280.8, 280.9, 285.22, or 285.3 plus secondary diagnoses for the condition causing the anemia) with intolerance to oral iron or unsatisfactory response to oral iron (statement must be included on the claim as to why patient needs IV over oral); treatment of iron-deficiency anemia in adults with non-dialysis-dependent chronic kidney disease (Primary DX from one of the following – 280.0, 280.8, 280.9 plus Secondary DX from one of the following – 585.3, 585.4, 585.5)	00517-0650-01	750mg/15ml	$795.000	$755.250	Effective July 2013
Firazyr (see Icantibant)
Firmagon (see Degarelix)
Flagyl IV (see Metronidazole In Nacl.)
Floxin IV (see Ofloxacin)
Flumazenil (Mazicon, Romazicon)		0.1 mg	$0.915	$0.869
Flumazenil (Mazicon, Romazicon)		0.5 mg	$42.830	$40.689
Folic Acid		5 mg	$2.171	$2.062
Folotyn (see Pralatrexate)
Fospropofol Disodium injection (Lusedra)		35 mg	$1.272	$1.208
Gammaked injection		500 mg	$37.484	$35.610
Gammaplex (see Human Immune Globulin Intravenous)
Glucarpidase		10 units	$233.730	$222.044
Glycopyrrolate (Robinul)		0.2 mg	$0.576	$0.547
Golimumab (See Simponi Aria)
Halaven (see Eribulin Mesylate)
** Heparin Sodium		100 units	$0.032	$0.030
Hetastarch Sodium Cl., 6 gm/500 ml		6 gm	$23.040	$21.888
Hexaminolevulinate Hydrochloride - Covered for ICD-9's 188.0 through 188.9		100 mg, per study dose	$741.576	$704.497
Hizentra (see Immune Globulin Subcutaneous)
Human Immune Globulin Intravenous (Gammaplex)		IV
Hydroxocobalamin - Covered when billed with J9305.		1000 mcg/ml	$1.212	$1.151
Icantibant (Firazyr) - Usually considered self-administered
Ilaris (see Canakinumab)
Immune Globulin (see Bivigam)	59730-6503-01	100 ml			added June 2013
Immune Globulin (see Bivigam)	59730-6502-01	50 ml			added June 2013
** Inamrinone Lactate		5 mg	$4.050	$3.848
IncobotulinumtoxinA (Xeomin) - Covered for the treatment of Genetic torsion dystonia (333.6) and Blepharospasm (333.81)		1 Unit
Injectafer (see Ferric Carboxymaltose)
INTEGRA™ Bilayer Matrix Wound Dressing - Covered Indications = 757.39, 941.20-941.21, 941.24-941.31, 941.34-941.41, 941.44-941.51, 941.54-941.59, 942.20-942.59, 943.20-943.59, 944.20-944.58, 945.20-945.59, 946.2-946.5, 948.00-948.99		1 sq cm	$29.169	$27.711
Invega® Sustenna® (see Paliperidone Palmitate injection)
Ipilimumab (Yervoy) - Covered for unresectable or metastatic melanoma.		1mg
Isoproterenol Hydrochloride (Isuprel)		0.2 mg	$2.250	$2.138
Isoptin IV (see Verapamil Hydrochloride)
Istodax (see Romidepsin)
Isuprel (see Isoproterenol Hydrochloride)
Jetrea (Ocriplasmin) Covered indication 379.27 (vitreomacular adhesion)		0.2 ml SDV	$4,187.000	$3,977.650
Jevtana® (see Cabazitaxel)
Kadcyla (see Ado-Trastuzumab Emtansine)					Added March 2013
Kalbitor (see Ecallantide)
Kenalog (see Triamcinolone Acetonide)
Keppra intraveneous (see Levetiracetam)
Ketamine Hydrochloride (Ketalar) Allowed when billed on same day as 20550-20610, 62289, 62298, 62368, 95990, or 96530.		10 mg	$0.067	$0.064
Kyprolis (see Carfilzomib)
Krystexxa (see Pegloticase)
Labetalol Hydrochloride (Trandate, Normodyne) Covered if given IV in the office for control of BP in severe hypertension. Patient is normally switched to oral for maintainance doses.		5 mg	$0.118	$0.112
** Levobupivacaine Hydrochloride (Chirocaine) Allowed separately when billed on same day as 51700, 51720, 62310, 62311, 62318, 62319, 62368, 64400 - 64484, 64505-64530, 76003, 95990, or 96530. Not payable separately when billed with any other procedures		2.5 mg/ml	$0.310	$0.295
** Levophed Bitartrate (see Norepinephrine Bitartrate)
** Levothyroxine Sodium (Synthroid) Need statemnt on claim as to why patient can't take oral form of drug.		0.5 mg	$62.010	$58.910
Lidocaine - Allowed separately when billed on same day as 51700, 51720, 62310, 62311, 62318, 62319, 62368, 64400 - 64484, 64505 - 64530, 77033, 95990, or 96530. Not payable when billed with any other procedure.		1 ml	$0.143	$0.136
Lopressor (see Metoprolol Tartrate)
Lusedra (see Fospropofol Disodium injection)
Magnesium Chloride Hexahydrate-Covered for the correction of hypomagnesemia (275.2) When administered in the physician’s office		1 gram	$0.328	$0.311
Mandol (see Cefamanadole Nafate)
Marqibo (see VinCRIStine sulfate Liposome)	20536-0322-01	0.16mg/ml	#######
Mazicon (see Flumazenil)
Methylcobalamin Injection					Code-J3420
Methylnaltrexone Bromide (Relistor) Non-covered by carrier.
Metoprolol Tartrate (Lopressor) Covered when given IV with Dobutamine J1250 during Dobutamine Stress Test.		1 mg	$0.309	$0.294
Metronidazole Hcl. (Flagyl IV) IV in the office. Covered for ICD-9's= 001.0-009.3, 040.0-041.9, 481-482.9, 567.0-567.9, 599.0-599.9, 615.0-615.9.		500 mg	$0.900	$0.855
Miconazole (Monistat IV) 10 mg			Invoice	Invoice
Minocycline Hydrochloride (Non-covered oral drug)
Monistat IV (see Miconazole)
Morrhuate Sodium		50 mg	$2.105	$2.000
Myozyme (see Alglucoside Alfa)
Nafcillin Sodium (Nallpen) (Dosage Change from 500 mg to 1 gm)		1 gm	$8.058	$7.655
Nalmefene Hydrochloride (Revex)		10 mcg	$0.276	$0.262
Netilmicin Sulfate (Netromycin), 150 mg			Invoice	Invoice
Nexium IV (see Esomeprazole Sodium)
Nitroglycerin IV – Allowed in emergency situations.		5 mg	$0.416	$0.395
Nodolo & Tusal (see Sodium Thiosalicylate)
** Norepinephrine Bitartrate (Levophed Bitartrate) Allow in emergency situations.		1 mg	$2.161	$2.053
Norcuron (see Vecuronium Bromide)
Normal Saline (Sterile Water)		50 ml	$1.430	$1.359
Normodyne (see Labetalol Hydrochloride)
Nplate™ (see Romiplostim)
Nulojix (see Beltatacept)
Ocriplasmin Intraviteral Injection (see Jetrea)
Ofloxacin (Floxin IV), 20 mg			Invoice	Invoice
Olanzapine short-acting intramuscular injection (Zyprexa IM) Covered indications = 295.01 - 295.84 when administered in the physicians office.		0.5 mg	$1.201	$1.141	Updated July 2014
Omacetaxine Mepesuccinate (Synribo) covered indications 205.10 without having achieved remission, failed remission or 205.12 in relapse		3.5 mg	$885.100	$840.845
Ontak (see Denileukin Difitox)
Optison			Invoice	Invoice
Orencia (see Abatacept)
** Oxychlorosene Sodium (Clorpactin WCS-90)		1 gm	$1.850	$1.758
Ozurdex (see Dexamethasone Intravitreal Implant)
Pantoprazole Sodium, IV (Protonix IV) Need statement as to why patient is not able to take oral form.		40 mg	$4.511	$4.285
** Peginterferon Alfa-2A/Isopropyl Alchol (Pegasys®) Covered indication 070.54 when administered in the office.		180mcg/ml	$480.273	$456.259
Peginterferon Alfa-2B (PEG-Intron) 50 mcg Covered indication 070.54 when administered in the office.		50 mcg	$320.610	$304.580
** Peginterferon Alfa-2B, 80mcg Covered indication 070.54 when administered in the office.		80 mcg	$336.600	$319.770
** Peginterferon Alfa-2B, 120mcg Covered indication 070.54 when administered in the office.		120 mcg	$353.460	$335.787
** Peginterferon Alfa-2B, 150mcg Covered indication 070.54 when administered in the office.		150 mcg	$371.120	$352.564
Pegloticase (Krystexxa) When billed with J3490 or J3590, covered for chronic gout, ICD-9's 274.00 through 274.03		1mg
** Pegvisomant for Injection (Somavert) Considered Usually Self-Administered
Pepcid (see Famotidine)
Perjeta (see Pertuzumab)
Pertuzumab (Perjeta) Covered ICD-9 174.0 - 175.9 in combination with Trastuzumab J9355 and Docetaxel J9171		10 mg/ml	$102.092	$96.987
Potassium Acetate		2 meq	$0.027	$0.026
Potassium Phosphate		3 mmol	$0.043	$0.041
Procaine Hydrochloride		1%	$2.360	$2.242
Procaine Hydrochloride		2%	$3.400	$3.230
Prolia ™ (see Denosumab)
Propofol (Diprivan)		10 mg	$0.117	$0.111
Protonix IV (see Pantoprazole Sodium)
Provenge (see Sipuleucel-T)
Qutenza (see Capsaicin 8% Patch)
** R-Gene 10 (see Arginine Hcl.)
Radium Ra 223 dichloride (Xofigo), A9699 – Approved FDA indications of castration-resistant prostate cancer (185) plus symptomatic bone metastases (198.5 secondary malignant neoplasm of bone and bone marrow). The patient’s records should contain documentation regarding no known visceral metastatic disease		PER TREATMENT DOSE	#######	$11,580.500	Updated 05/2014
Relistor (see Methylnaltrexone Bromide)
Revex (see Nalmefene Hydrochloride)
Rexolate & Arthrolate (see Sodium Thiosalicylate)
RiaSTAP (see Fibrinogen Concentrate Human)
Rifampin		600 mg	$70.088	$66.584
Robinul (see Glycopyrrolate)
Romazicon (see Flumazenil)
Sarracenia Purpura Non-covered by Carrier
Sensorcaine, Sterile (see Bupivicaine, Sterile)
Simponi Aria (Golimimab) Covered for moderately to severely active Rheumatoid Arthritis (RA) (714.0-714.2, 714.30-714.89) in combination with methotrexate – 2 mg/kg IV over 30 minutes weeks 0 and 4 and then every 8 weeks	57894-0350-01	50 mg	$1,219.000	$1,158.050	Added July 2013
Sipuleucel-T (Provenge) ICD-9 = 185		Per infusion (minimum 50 million cells)
Sodium Acetate		2 meq	$0.043	$0.041
** Sodium Bicarbonate, PF (NACH03)		7.5%/50 ml	$2.730	$2.594
Sodium Bicarbonate, 8.4% (NACH03)		50 ml	$0.122	$0.116
Sodium Chloride, Hypertonic		250 cc	$0.700	$0.665
Sodium Hyaluronate/Chrondroitin Sulfate(Viscoat)
** Sodium Tetradecyl Sulfate (Sotradecol)			Invoice	Invoice
** Sodium Thiosalicylate (Rexolate & Arthrolate, Nodolo & Tusal)		50 mg	$0.970	$0.922
Sodium Thiosulfate		100 mg	$0.155	$0.147
Soliris (see Eculizumab)
Somatuline Depot (see Lanreotide)
** Somavert (see Pegvisomant for Injection)		5 cc	$0.052	$0.049
Stavzor- Non covered by carrier
Stelara (see Ustekinumab)
Sterile Saline / Water		1000 ml	$5.640	$5.358
** Sterile Saline / Water, 1000 ml		50mcg/ml	$9.810	$9.320
** Sufentanil Citrate (Sufenta) Separate payment allowed when billed with 62310, 62311, 62318, 62319, 76005, 95990, or 96530. If billed with any other procedures, it will be considered part of the procedure and separate payment will not be allowed.
Sulfamethoxazole/Trimethoprim (SMZ-TMP) Documentation as to why the patient needs to be on IV infusion instead of oral medication, must be in block 19 or as an attachment for paper claims or in the notepad for EMC claims.		400 - 80 mg	$0.312	$0.296
SurgiMend		0.5 sq cm	$11.961	$11.363
Synribo (see Omacetaxine Mepesuccinate)
Synthroid (see Levothyroxine Sodium)
Synvisc-One (see Hylan G-F 20)
Tagamet (see Cimetidine Hydrochloride)
Taliglucurase Alfa		10 units	$30.904
Tenormin (see Atenolol)
Tensilon (see Edrophonium Chloride)
Testosterone		37.5 mg	$0.110	$0.105
** Testosterone Pellets (Testopel)		Per Pellet	Invoice	Invoice
Tetanus Toxoid (use codes 90702, 90703, or 90718)
Tetracycline			Invoice	Invoice
Torisel (see Temsirolimus)
Trandate (see Labetalol Hydrochloride)
Treanda (see Bendamustine Hydrochloride)
Truxton (see Prednisolone Acetate)
Tyvaso (see Treprostinil inhalation)
Vaccinia IVIG (see Human Immune Globulin Intravenous)
Valproate Sodium (Depacon) IV, Covered ICD9's = 345.00 - 345.91, Allowed when administered IV, in the physician's office. (Dosage change from 500 mg to 100 mg)		100 mg	$0.558	$0.530
Valproic Acid- Non covered by carrier
Vasopressin		20 units	$3.821	$3.630
Vasotec IV (see Enalaprilat)
Vectibix (see Panitumumab)
Vecuronium Bromide (Norcuron)		1 mg	$0.354	$0.336
Verapamil Hydrochloride (Isoptin IV)		2.5 mg	$3.167	$3.009
VIBATIV™ (see Telavancin Injection)
Vincristine Sulfate Liposome (Marquibo) covered ICD-9: 204.00-204.02		0.16mg/ml	#######
Viscoat (Sodium Hyaluronate/Chondroitin Sulfate) Non-covered by carrier
** Vitamin B Complex		Up to 3 ml	$0.930	$0.884
** Vitamin C (see Ascorbic Acid) (Cenolate) Non-covered by Carrier
Vivaglobin (see Immune Globulin Subcutaneous)
VPRIV™ (see Velaglucerase alfa for injection)
Wilate (Human coagulation factor VIII (FVIII) and von Willebrand factor (VWF) powder and solvent for solution for injection) Covered ICD-9: 286.4		1 IU VWF:RCO
Xeomin (see IncobotulinumtoxinA)
Xgeva (see Denosumab)
Xiaflex (see Collagenase Clostridum Histolyticum)
Xofigo (see Radium Ra 223 dichloride )
Xyntha (see Antihemophilic Factor (Recomb) Plasma/Albumin-Free)
Yervoy (see Ipilimumab)
Zaltrap (see Ziv-Aflibercept)
Ziv-Aflibercept (Zaltrap) covered ICD-9 153.0 - 153.7 or 154.0 - 154.2		1 mg.	$11.098
Zortress (see Everolimus)
Zyprexa IM (see Olanzapine)
HOCM <= 149 MG/ML		1 ml	$0.041	$0.039
HOCM 200 - 249 MG/ML		1 ml	$0.093	$0.088
HOCM 250 - 299 MG/ML		1 ml	$0.100	$0.095
HOCM 300 - 349 MG/ML		1 ml	$0.104	$0.099
HOCM 350 - 399 MG/ML		1 ml	$0.107	$0.102
HOCM >= 400 MG/ML		1 ml	$0.191	$0.181

License for Use of "Physicians' Current Procedural Terminology", (CPT) Fourth Edition

AMA Disclaimer of Warranties and Liabilities.

CMS Disclaimer

POINT AND CLICK LICENSE FOR USE OF "CURRENT DENTAL TERMINOLOGY", ("CDT")

2013 3rd Quarter Payment Allowance Limits for Not Otherwise Classified (NOC) Drugs

spacer